Centessa Pharmaceuticals’ (CNTA) “Buy” Rating Reaffirmed at Guggenheim

Guggenheim restated their buy rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research note published on Wednesday,Benzinga reports. They currently have a $28.00 price target on the stock.

Several other analysts have also recently issued reports on the company. TD Cowen began coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Morgan Stanley restated an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $26.00.

Centessa Pharmaceuticals Stock Down 8.0 %

CNTA stock opened at $14.54 on Wednesday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a 50 day simple moving average of $16.49 and a 200-day simple moving average of $16.42. The company has a market capitalization of $1.92 billion, a P/E ratio of -9.50 and a beta of 1.54. Centessa Pharmaceuticals has a twelve month low of $7.75 and a twelve month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. On average, equities research analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $16.69, for a total transaction of $917,950.00. Following the completion of the transaction, the chief executive officer now directly owns 276,017 shares of the company’s stock, valued at $4,606,723.73. The trade was a 16.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Gregory M. Weinhoff sold 11,742 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $16.47, for a total transaction of $193,390.74. Following the completion of the sale, the insider now owns 159,782 shares in the company, valued at $2,631,609.54. The trade was a 6.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 260,168 shares of company stock worth $4,309,568 in the last 90 days. 11.59% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. acquired a new position in Centessa Pharmaceuticals during the 4th quarter worth $31,000. GAMMA Investing LLC lifted its holdings in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after purchasing an additional 865 shares during the period. Barclays PLC grew its position in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after buying an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $162,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $171,000. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.